 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Alkermes plc (ALKS) is an Irish biopharmaceutical company. 
The firm researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.
Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells.
It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH.
Shares are breaking out of their bullish "cup and handle" and are expected to move higher in price.
On July 28th, Alkermes reported 2nd Quarter June 2021 earnings of $0.13 per share on revenue of $303.7 million. The consensus estimate was a loss of $0.02 per share on revenue of $278.7 million. Revenue grew 22.7% on a year-over-year basis.
The company said it expects 2021 non-GAAP earnings of $0.52 to $0.70 per share on revenue of $1.145 billion to $1.185 billion. The company's previous guidance was earnings of $0.37 to $0.62 per share on revenue of $1.10 billion to $1.17 billion and the current consensus earnings estimate is $0.51 per share on revenue of $1.14 billion for the year ending December 31, 2021.
Entry Point: $29.00
Trading Range: $15.35 to $29.11
Stop Loss: $27.00
Target Price: $32.00
